Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer

Journal of the National Cancer Institute

Volumn 103, Issue 2, 2011, Pages 160-161

  Muggia, Franco ^a   Cannon, Timothy ^a   Safra, Tamar ^a   Curtin, John ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; CARBOPLATIN; DOXORUBICIN;

CANCER RECURRENCE; DYSPLASIA; GENE MUTATION; HUMAN; KIDNEY DISEASE; LETTER; LONG TERM CARE; MOUTH CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SUBLINGUAL DYSPLASIA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; RECURRENCE; RENAL INSUFFICIENCY;

EID: 79251508326     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq484     Document Type: Letter

References (7)

1. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum based chemotherapy for ovarian cancer; implications for patient management and clinical trial design. J Clin Oncol. 2004;22(15): 3120-3125.
2. Harrison ML, Gore ME, Spriggs D, et al. Duration of second or greater complete clinical remission in ovarian cancer: exploiting potential endpoints clinical trials. Gynecol Oncol. 2007;106(3):469-475.
3. Pujade-Lauraine E, Wagner U, Aavall-Lundquist E, et al. Pegylated liposomal doxo-rubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-3329.
4. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C. Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18(17):3093-3100.
5. Andreopolou E, Gaiotti D, Kim E, et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol. 2007;18(4):716-721.
6. Martin-Carbonero L, Palacios R, Valencia E, et al. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis. 2008;47:410-417.
7. Baumgartner RA, Safra T, Borgato L, et al. Prevalence of renal dysfunction and hypertension in recurrent eptihelial ovarian cancer: a retrospective analysis. Gynecol Oncol. 2010; 116(3):S2-S169.